WithdrawnNot Applicable

Rivet PVS Therapy in Group 2 PH-HFpEF Canada

Stopped: Commercial decision

Canada0Started 2023-10

Plain-language summary

This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with symptomatic pulmonary hypertension.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. mPAP \> 20 mmHg at rest
✓. mPAP/CO slope \> 3 mmHg/L/min with exercise
✓. NYHA HF Class II with history \> II, or Class III, or ambulatory Class IV
✓. ≥ 1 HF hospitalization, or healthcare facility with IV diuretics or intensification of oral diuresis for HF within 12 months, or NT-pro BNP value \> 400 pg/mL in normal sinus rhythm or \> 750 pg/mL in atrial fibrillation in past 6 months

Exclusion criteria

✕. Greater than moderate RV dysfunction as assessed by TTE and/or MRI
✕. RV FAC \< 35%
✕. TAPSE \< 14 mm via TTE
✕. RV size severely enlarged compared to LV size as estimated by TTE and/or MRI
✕. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF
✕. If BMI \< 30, Cardiac Index \< 2.0 L/min/m2
✕. If BMI ≥ 30, Cardiac Index \< 1.8 L/min/m2
✕. Requires continuous intravenous inotropic infusion

What they're measuring

Rate of Major Adverse Events

Timeframe: 1 month

Rate of Technical Success of the Rivet Shunt Implantation Procedure

Timeframe: At time of procedure

Trial details

NCT IDNCT05332873

SponsorNXT Biomedical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-05

View on ClinicalTrials.gov More Heart Failure trials